Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer
Status:
Active, not recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This is a open-label, single-arm study to investigate the safety and efficacy of Total
neoadjuvant chemotherapy with camrelizumab, an anti-PD-1 antibody drug following short course
radiotherapy in patients with rectal cancer.